Poor
Mostly Aligned
Patient Risk:
Low
Summary
Overall alignment is poor due to multiple claims being unsupported or absent from the label; several inactive ingredient details asserted in the claims do not appear in the label, and no comprehensive safety/warning content is covered by the claims.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a prescription medication used to lower cholesterol levels in the blood.
Indications and Usage (1)
Atorvastatin is a statin.
Mechanism of Action (12.1)
Lipitor belongs to a class of drugs called statins, which work by inhibiting the production of cholesterol in the liver.
Mechanism of Action (12.1)
Lipitor contains inactive ingredients including Microcrystalline cellulose.
11 Description
Lipitor contains inactive ingredients including croscarmellose sodium.
11 Description
Lipitor contains inactive ingredients including hydroxypropyl cellulose.
11 Description
Lipitor contains inactive ingredients including hydroxypropyl methylcellulose.
11 Description
Lipitor contains inactive ingredients including titanium dioxide.
11 Description
Lipitor contains inactive ingredients including polysorbate 80.
11 Description
Unsupported Statements
Lipitor contains inactive ingredients including iron oxide yellow.
Iron oxide yellow is not listed among Lipitor's inactive ingredients in section 11.
Lipitor contains inactive ingredients including iron oxide red.
Iron oxide red is not listed among Lipitor's inactive ingredients in section 11.
Lipitor contains inactive ingredients including iron oxide black.
Iron oxide black is not listed among Lipitor's inactive ingredients in section 11.
Lipitor contains inactive ingredients including polysorbate 40.
Polysorbate 40 is not listed among Lipitor's inactive ingredients in section 11.
Lipitor contains inactive ingredients including carnauba wax.
Carnauba wax is not listed among Lipitor's inactive ingredients in section 11.
Lipitor contains inactive ingredients including ethylcellulose.
Ethylcellulose is not listed among Lipitor's inactive ingredients in section 11.
Lipitor contains inactive ingredients including ethanol.
Ethanol is not listed among Lipitor's inactive ingredients in section 11.
Some Lipitor formulations may contain gelatin, which is derived from animal bones and connective tissue.
Gelatin is not listed among Lipitor's inactive ingredients in section 11.
Carnauba wax is derived from the leaves of the carnauba palm tree.
Label does not provide botanical/source details for carnauba wax.
Some manufacturers may use animal-derived products in the processing stage.
Label does not discuss manufacturing-source disclosures.
Polysorbate 80 is often derived from animal products, such as gelatin or lanolin.
Label does not provide source derivation for polysorbate 80.
Lipitor patent has expired, which means that generic versions of the medication are available.
Patent status and generic availability are not described in labeling.
Generic versions may not have the same inactive ingredients as the brand-name version.
Brand vs generic excipient differences are not discussed in labeling.
Rosuvastatin (Crestor) or simvastatin (Zocor) may have different inactive ingredients that align better with vegan values.
Label does not compare Lipitor to other statins or discuss vegan alignment.
If you're taking Lipitor and are concerned about its ingredients, consult with your healthcare provider about switching to a different medication.
No consumer-directed guidance about ingredient switching in labeling.
Lipitor's active ingredient, atorvastatin, is synthetic and vegan-friendly.
Label does not address vegan-friendliness of active ingredient.
Lipitor's active ingredient is vegan-friendly, but some inactive ingredients raise concerns for vegans.
Label does not address vegan considerations.
Contradictions
Important Omissions
Detailed contraindications such as active liver disease and elevations in hepatic transaminases.
Importance:
High
Dose-specific safety details (starting dose, titration, maximum dose, hepatic impairment adjustments).
Importance:
High
Pregnancy risk counseling (Section 8.1).
Importance:
High
Pediatric safety information beyond generic confirmation (Section 8.4).
Importance:
High
Important interaction-related risk (myopathy with concomitant statin or fibrate use) related to dosing safety and warnings.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Some accurate claims align with the label, but numerous omissions leave out contraindications, warnings, and interactions that are material to patient safety.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Significant omissions and multiple unsupported or label-absent claims regarding inactive ingredients and safety content.
Suggested Improvement
Constrain claims to those explicitly supported by the label; include all relevant label sections (contraindications, warnings, drug interactions, specific populations, adverse reactions, administration) and verify inactive ingredient lists against section 11; exclude vegan/sourcing claims not present in the label.